Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

GE Healthcare Strengthens R&D Efforts in Alzheimer’s Disease

Published: Friday, April 13, 2012
Last Updated: Friday, April 13, 2012
Bookmark and Share
A Research Collaboration with Clino Ltd., a biotechnology venture from Tohoku University on the development of novel Tau imaging tracers.

Collaboration aims to increase the accuracy of pre-symptomatic diagnoses, and discover pharmaceuticals for PET exams and contributing to new treatments on the molecular level.

GE Healthcare (Chalfont St. Giles, U.K.; John Dineen, president and CEO), Medical Diagnostics business has entered into research collaboration with Clino Ltd. (Sendai, Miyagi Prefecture; Noriaki Satake, president), a venture by Tohoku University to discover in vivo imaging tracers for tau proteins that accumulate in the brains of Alzheimer’s Disease patients.

Yukitsuka Kudo, head of imaging at Clino and a professor at Tohoku University Innovation of New Biomedical Engineering Center, explains the significance of the research project: “The development of radiotracers for tau examinations involves a number of hurdles, and we’re hoping that our joint research with GE’s worldwide operation will enable us to serve as a bridge that will speed the further evolution of these pharmaceuticals, as well as their progression through clinical and therapeutic trials.”

Professor Hiroyuki Arai of the Institute of Development, Aging and Cancer at Tohoku University is the leading domestic researcher on Alzheimer’s and the first person in the world to succeed in detecting tau proteins in cerebrospinal fluid and argue for their significance as surrogate biomarker. Dr. Arai stresses the crucial nature of tau imaging in Alzheimer’s diagnoses: “Research data on PET imaging of amyloid are currently being accumulated, and the thinking now is that if we can conduct additional tau PET imaging on healthy subjects who have tested positive in amyloid PET exams, it will become possible to identify those with high risk of converting to Alzheimer’s. This could lead to diagnoses of pre-clinical stage Alzheimer’s disease’, which may enable prevention before the onset of symptoms.”

As of 2010, there were a total of approximately 35.6 million confirmed cases of Alzheimer’s disease worldwide, and projections indicate that the total will reach 115.4 million cases by 2050.(1) In Japan, which is leading the world in terms of the advance of population aging, there were approximately 2 million cases in 2010, with a projected 3.25 million expected by 2020(2). Alzheimer’s is thought to be caused by accumulations within the brain of beta amyloid and tau proteins. Beta amyloid plaques are thought to begin accumulating within the brain 30 years before symptoms appear, and tau proteins ten years prior.

“The collaboration we are announcing today is part of our ongoing effort to understand and identify Alzheimer’s disease in its very early stages,” said Pascale Witz, CEO of GE Healthcare Medical Diagnostics. “The combination of our different business offerings positions us well to offer an integrated global diagnostics solution for the next generation of therapies. We are working with pharma to understand their strategic needs and design solutions accordingly.”

GE Healthcare already provides the worldwide supply of (11)C-PIB, a PET contrast agent for beta amyloid detection developed by the University of Pittsburgh in 2003 and for which GE Healthcare has obtained exclusive rights of utilization. In addition, if the new joint venture with Clino results in the identification of agents that can distinguish tau accumulation, it will become possible to diagnose the level of severity of Alzheimer’s symptoms. It would also be expected to enable the development of drugs by the pharmaceutical industry and research institutes that would target tau proteins on the molecular level.

Further, GE Healthcare and Clino will consider collaborations with other companies and research institutes developing tau protein therapies. These are among the many efforts aimed at contributing to the early, precise diagnosis and treatment of Alzheimer’s.

In addition to development of pharmaceuticals, GE Healthcare is currently providing diagnostic imaging devices such as PET and magnetic resonance imaging (MRI) scanners in support of the detection of cognitive diseases including Alzheimer’s. They have also been supporters from the outset of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a clinical observational research project designed to generate standards for Alzheimer’s diagnosis and assessment of the degree to which the disease has progressed. They are moving ahead with a diverse range of efforts toward the imaging evaluation of cognitive diseases around the world including in Japan.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare to Collaborate with GlaxoSmithKline on Commercial Oncology Testing
The collaboration aims to improve access to diagnostic testing for cancer patients by establishing a network of clinical laboratories to identify genetic mutations associated with different tumour types.
Tuesday, September 30, 2014
GE Acquires Strategic Assets from Thermo
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses.
Monday, January 06, 2014
GE Healthcare Acquires Unisyn Medical Technologies’ Transactional Business
The proprietary products and services from Unisyn will be integrated into GE Healthcare’s Global Services organization.
Thursday, May 30, 2013
GE Healthcare Completes Acquisition of SeqWright, Inc., Expanding Capabilities in Fast Growing Molecular Diagnostic Segment
Addition of high growth company builds on Clarient’s biopharma service capabilities and provides platform to offer sequencing-based clinical diagnostics in the future.
Thursday, April 05, 2012
GE Healthcare and M+W Group Form Strategic Alliance in Vaccines, Insulin and Biopharmaceuticals
Companies to help emerging nations develop their own manufacturing capabilities for essential biopharmaceuticals, reducing reliance on imports.
Wednesday, December 14, 2011
GE Healthcare to Invest $1 Billion in New Oncology Solutions
Expanding advanced cancer diagnostic and molecular imaging capabilities.
Saturday, September 17, 2011
GE Healthcare Appoints Kieran Murphy as Life Sciences CEO, Successor to Peter Ehrenheim
On 1 April 2011, Kieran Murphy will be promoted to succeed current Life Sciences President and CEO Peter Ehrenheim who will retire from GE after a transition period on July 31 2011.
Tuesday, February 22, 2011
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
Nanomedicine for Breast Cancer Treatment
Using nanoparticles measuring only billionths of a meter in size, doctors are able to deliver drug molecules directly to the affected tissue.
Clamping Down on Biomolecules
Physicists have developed a novel nanotool that provides a means of characterizing the mechanical properties of biomolecules.
MRIs for Fetal Health
Algorithm could help analyze fetal scans to determine whether interventions are warranted.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Inflammation Test May Predict Cardiovascular Disease
An assessment combining measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos